Pulmatrix, Inc. Files Q3 2024 10-Q Report
Ticker: PULM · Form: 10-Q · Filed: Nov 8, 2024 · CIK: 1574235
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Pulmatrix filed its Q3 10-Q. Check financials.
AI Summary
Pulmatrix, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results for the third quarter and the first nine months of the year. Key financial data and operational updates are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Pulmatrix, Inc., crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Pulmatrix faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q3 2024 — Reporting Period (The financial results cover the third quarter of 2024.)
- Nine Months Ended September 30, 2024 — Year-to-Date Period (The filing also includes financial data for the first nine months of 2024.)
Key Players & Entities
- Pulmatrix, Inc. (company) — Filer of the 10-Q report
- 20240930 (date) — End of the reporting period
- 20241108 (date) — Filing date of the report
- Framingham, MA (location) — Company's business and mailing address
FAQ
What were Pulmatrix, Inc.'s total revenues for the nine months ended September 30, 2024?
The filing does not explicitly state the total revenues for the nine months ended September 30, 2024, in the provided text snippet.
What is the company's primary business activity?
Pulmatrix, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
When was Pulmatrix, Inc. formerly known as Ruthigen, Inc.?
The company changed its name from Ruthigen, Inc. on April 11, 2013.
Where is Pulmatrix, Inc. located?
Pulmatrix, Inc. is located at 945 Concord Street, Suite 1217, Framingham, MA 01701.
What is the fiscal year end for Pulmatrix, Inc.?
The fiscal year end for Pulmatrix, Inc. is December 31.
Filing Stats: 4,550 words · 18 min read · ~15 pages · Grade level 17.6 · Accepted 2024-11-08 08:20:41
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PULM The NASDAQ Stock Mar
Filing Documents
- form10-q.htm (10-Q) — 717KB
- ex31-1.htm (EX-31.1) — 11KB
- ex32-1.htm (EX-32.1) — 4KB
- 0001493152-24-044163.txt ( ) — 3545KB
- pulm-20240930.xsd (EX-101.SCH) — 31KB
- pulm-20240930_cal.xml (EX-101.CAL) — 45KB
- pulm-20240930_def.xml (EX-101.DEF) — 98KB
- pulm-20240930_lab.xml (EX-101.LAB) — 244KB
- pulm-20240930_pre.xml (EX-101.PRE) — 183KB
- form10-q_htm.xml (XML) — 462KB
—FINANCIAL INFORMATION
PART I—FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (unaudited) 1 Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 1 Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023 2 Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2024 and 2023 3 Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.
Controls and Procedures
Controls and Procedures 27
—OTHER INFORMATION
PART II—OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 28 Item 1A.
Risk Factors
Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults Upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 28
SIGNATURES
SIGNATURES 29 i PART I—FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements. PULMATRIX, INC. Consolidated Balance Sheets (in thousands, except share and per share data) September 30, 2024 December 31, 2023 (unaudited) Assets Current assets: Cash and cash equivalents $ 10,782 $ 19,173 Accounts receivable 23 928 Prepaid expenses and other current assets 641 742 Total current assets 11,446 20,843 Property and equipment, net - 1,158 Operating lease right-of-use asset - 10,309 Long-term restricted cash 10 1,472 Other long-term assets 54 176 Total assets $ 11,510 $ 33,958 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 373 $ 1,915 Accrued expenses and other current liabilities 217 947 Operating lease liability - 429 Deferred revenue - 618 Total current liabilities 590 3,909 Deferred revenue, net of current portion - 3,727 Operating lease liability, net of current portion - 8,327 Total liabilities 590 15,963 Commitments and contingencies (Note 10) - - Stockholders' equity: Preferred Stock, $ 0.0001 par value — 500,000 shares authorized; 6,746 shares designated Series A convertible preferred stock; no shares issued and outstanding at September 30, 2024 and December 31, 2023 - - Common stock, $ 0.0001 par value — 200,000,000 shares authorized; 3,652,285 shares issued and outstanding at September 30, 2024 and December 31, 2023 - - Additional paid-in capital 306,090 305,592 Accumulated deficit ( 295,170 ) ( 287,597 ) Total stockholders' equity 10,920 17,995 Total liabilities and stockholders' equity $ 11,510 $ 33,958 The accompanying footnotes are an integral part of these condensed consolidated financial statements. 1 PULMATRIX, INC. Consolidated (in thousands, except share and per share data) (unaudited) 2024 2023 2024 2023 Three Months Ended September 3